Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,950,368 papers from all fields of science
Search
Sign In
Create Free Account
irofulven
Known as:
HMAF cpd
, HMAF
, 6-Hydroxymethylacylfulvene
Expand
A semisynthetic sesquiterpene derivative of illudin S, a natural toxin isolated from the fungus Omphalotus illudens. Irofulven alkylates DNA and…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
9 relations
Broader (3)
Antineoplastic Agents, Alkylating
Radiation-Sensitizing Agents
Sesquiterpenes
Apoptosis
DNA
DNA Alkylation
DNA Strand Break
Expand
Narrower (1)
MGI-114
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Sulfotransferase-independent genotoxicity of illudin S and its acylfulvene derivatives in bacterial and mammalian cells
H. Glatt
,
K. Pietsch
,
S. Sturla
,
W. Meinl
Archives of Toxicology
2013
Corpus ID: 253715523
Acylfulvenes are a class of antitumor agents derived from illudin S, a sesquiterpenoid toxin isolated from mushrooms of the genus…
Expand
2010
2010
Enantioselective total syntheses of acylfulvene, irofulven, and the agelastatins
D. Siegel
2010
Corpus ID: 102099328
2009
2009
Irofulven – Halloween Trick or a Beacon of Light by Elinoar Shavit
E. Shavit
2009
Corpus ID: 46673398
The history of Irofulven, MGI Pharma’s novel anti-tumor drugcandidate, unfolds like a suspense story. It involves toxins, great…
Expand
2006
2006
Metabolism , and Routes of Excretion of Intravenous Irofulven in Patients with Advanced Solid Tumors
K. Rezai
,
A. Deroussent
,
+9 authors
E. Upres
2006
Corpus ID: 40516040
UPRES EA 3535 Pharmacology and New Treatments of Cancer, IFR 54, Institute Gustave Roussy, Villejuif, France. (AP, MR, GV…
Expand
2000
2000
Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan
M. Kelner
,
T. McMorris
,
L. Estes
,
K. Samson
,
N. Trani
,
J. MacDonald
Leukemia
2000
Corpus ID: 21254461
The illudin derivative MGI 114 (6-hydroxymethylacylfulvene or HMAF) is currently in phase II chemotherapeutic clinical trials for…
Expand
2000
2000
Evaluation of antidotes for extravasation injury produced by 6-hydroxymethylacylfulvene (MGI 114), a novel cytotoxic antitumor agent, in an intradermal toxicity model in rats
Richard F. Marshall
,
Larry E. Arthaud
,
J. Macdonald
Cancer Chemotherapy and Pharmacology
2000
Corpus ID: 25651873
Abstract MGI 114 (HMAF; 6-hydroxymethylacylfulvene) is a cytotoxic drug currently in phase II human clinical trials. As with…
Expand